Pre-clinical Development of Radiation Sensitizers for Patients with Glioblastoma
$851,098ZIAFY2025CANIH
Division Of Clinical Sciences - Nci
Investigators
Linked publications, trials & patents
Paper 38811596Paper 35740563Paper 35732578Paper 35565358Paper 35474866Paper 35260696Paper 35106480Paper 35073400Paper 34263489Paper 34158343Paper 33647370Paper 33554406Paper 32838071Paper 32702730Paper 32537176Paper 32277478Paper 32096067Paper 31987963Paper 30806515Paper 30059974Paper 21632852Paper 21472002Paper 20477491Paper 20387308Paper 20361469Paper 20109218Paper 19703306Paper 19549766Paper 19464627Paper 18798997Paper 18711189Paper 18414993Paper 18366457Paper 14612536Paper 12820778Paper 12702593
Abstract
This year we have focused on two pathways. The first is the KRAS pathway. We initially determined if any of our GBM cell lines or glioma stem-cell lines had the common KRAS mutation. They did not. So we focused on drugs that inhibit the function of intact KRAS. The in vitro work for this study is complete but we are unable to complete the animal work due to new restrictions. The second study has focused on the use of an LSD1 inhibitor. Much like the KRAS study, we have finished the in vitro cell work but have not been able to complete the animal studies. When this gets fixed we should be able to complete both studies.
View original record on NIH RePORTER →